Oral contraceptives in migraine

Expert Review of Neurotherapeutics

Volumn 9, Issue 3, 2009, Pages 381-393

  Allais, Gianni ^a   Gabellari, Maria Castagnoli ^a   De Lorenzo, Cristina ^a   Mana, Ornella ^a   Benedetto, Chiara ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Combined oral contraceptives; Ischemic stroke; Migraine; Safety; Thrombophilia; Tolerability

Indexed keywords

DESOGESTREL; ETHINYLESTRADIOL; GESTODENE; LEVONORGESTREL; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT;

CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DISEASE CLASSIFICATION; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; HEREDITY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INHERITANCE; LOW DRUG DOSE; MENSTRUAL MIGRAINE; MIGRAINE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; OBESITY; ORAL CONTRACEPTION; PRESCRIPTION; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SMOKING; THROMBOEMBOLISM; TREATMENT CONTRAINDICATION; TREATMENT WITHDRAWAL; CHEMICALLY INDUCED DISORDER; DRUG TOLERANCE; FEMALE; PATHOPHYSIOLOGY;

CONTRACEPTIVES, ORAL, COMBINED; DRUG TOLERANCE; FEMALE; HUMANS; MIGRAINE DISORDERS; RISK FACTORS;

EID: 66449111625     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.9.3.381     Document Type: Review

References (67)

1. Baillargeon JP, McClish DK, Essah PA, Nestler JE. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J. Clin. Endocrinol. Metab. 90(7), 3863-3870 (2005).
2. Burkman RT, Collins JA, Shulman LP, Williams JK. Current perspectives on oral contraceptive use. Am. J. Obstet. Gynecol. 185, S4-S12 (2001).
3. Loder EW, Buse DC, Golub JR. Headache as a side effect of combination estrogen-progestin oral contraceptives: a systematic review. Am. J. Obstet. Gynecol. 193, 636-649 (2005).
4. Mueller L. Predictability of exogenous hormone effect in subgroups of migraineurs. Headache 40, 189-193 (2000).
5. MacGregor EA, Igarashi H, Wilkinson M. Headaches and hormones: subjective versus objective assessment. Headache Q. 8, 126-136 (1997).
6. Cupini LM, Matteis M, Troisi E, Calabresi P, Bernardi G, Silvestrini M. Sex-hormone-related events in migrainous females. A clinical comparative study between migraine with aura and migraine without aura. Cephalalgia 15, 140-144 (1995).
7. Granella F, Sances G, Zanferrari C, Costa A, Martignoni GC. Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. Headache 33, 385-389 (1993).
8. Headache Classification Subcommittee of the International Headache Society (IHS). The International Classification of Headache Disorders (2nd edition). Cephalalgia 24(Suppl 1), 1-151 (2004).
9. Massiou H, MacGregor EA. Evolution and treatment of migraine with oral contraceptives. Cephalalgia 20, 170-174 (2000).
10. Allais G, Bussone G, Airola G et al. Oral contraceptive-induced menstrual migraine. Clinical aspects and response to frovatriptan. Neurol. Sci. 29(Suppl. 1), S186-S190 (2008).
11. Granella F, Sances G, Pucci E, Nappi RE, Ghiotto N, Nappi G. Migraine with aura and reproductive life events: a case control study. Cephalalgia 20(8), 701-707 (2000).
12. Fotherby K. Clinical experience and pharmacological effects of an oral contraceptive containing 20 micrograms oestrogen. Contraception 46, 477-488 (1992).
13. Gerais AS, Rushwan H. A crossover pill study among Sudanese women. Int. J. Gynaecol. Obstet. 23, 229-233 (1985).
14. Edelman DA, Kothenbeutel R, Levinski MJ, Kelly SE. Comparative trials of low-dose combined oral contraceptives. J. Reprod. Med. 28, 195-200 (1983).
15. Sulak PJ, Scow RD, Preece C, Riggs MW, Kuehl TJ. Hormone withdrawal symptoms in oral contraceptive users. Obstet. Gynecol. 95, 261-266 (2000).
16. Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: A meta-analysis. JAMA 284(1), 72-78 (2000).
17. Chan WS, Ray J, Wai EK et al. Risk of stroke in women exposed to low-dose oral contraceptives: a critical evaluation of the evidence. Arch. Intern. Med. 164(7), 741-747 (2004).
18. International Headache Society Task Force on Combined Oral Contraceptives & Hormone Replacement Therapy. Recommendations on the risk of ischemic stroke associated with use of combined oral contraceptives and hormone replacement therapy in women with migraine. Cephalalgia 20, 155-156 (2000).
19. World Health Organization. Family and Reproductive Health Programme. Improving access to quality care in family planning: medical eligibility criteria for contraceptive use (3rd edition.). World Health Organization. Geneva, Switzerland (2004).
20. ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. No 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet. Gynecol. 107, 1453-1472 (2006).
21. Pezzini A, Del Zotto E, Magoni M et al. Inherited thrombophilic disorders in young adults with ischemic stroke and patent foramen ovale. Stroke 34(1), 28-33 (2003).
22. Karttunen V, Hiltunen L, Rasi V, Vahtera E, Hillbom M. Factor V Leiden and prothrombin gene mutation may predispose to paradoxical embolism in subjects with patent foramen ovale. Blood Coagul. Fibrinolysis 14(3), 261-268 (2003).
23. Voetsch B, Damasceno BP, Camargo EC et al. Inherited thrombophilia as a risk factor for the development of ischemic stroke in young adults. Thromb. Haemost. 83(2), 229-233 (2000).
24. Longstreth WT Jr, Rosendaal FR, Siscovick DS et al. Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A). Stroke 29(3), 577-580 (1998).
25. Slooter AJ, Rosendaal FR, Tanis BC, Kemmeren JM, van der Graaf Y, Algra A. Prothrombotic conditions, oral contraceptives, and the risk of ischemic stroke. J. Thromb. Haemost. 3(6), 1213-1217 (2005).
26. Dentali F, Ageno W Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis. Blood 107, 2766-2773 (2006).
27. Martinelli I, Battaglioli T, Pedotti P, Cattaneo M, Mannucci PM. Hyperhomocysteinemia in cerebral vein thrombosis. Blood 102, 1362-1366 (2003).
28. Collaborative Group for the Study of Stroke in Young Women. Oral contraceptives and stroke in young women: associated risk factors. JAMA 231, 718-722 (1975).
29. Henrich JB, Horwitz RI. A controlled study of ischemic stroke risk in migraine patients. J. Clin. Epidemiol. 42, 773-780 (1989).
30. Marini C, Carolei A, Roberts RS et al. Focal cerebral ischemia in young adults: a collaborative case-control study.
31. The National Research Council Study Group. Neuroepidemiology 12(2), 70-81 (1993).
32. Tzourio C, Tehindrazanarivelo A, Iglésias S et al. Case-control study of migraine and risk of ischaemic stroke in young women. BMJ 310 (6983), 830-833 (1995).
33. Lidegaard O. Oral contraceptives, pregnancy, and the risk of cerebral thromboembolism: the influence of diabetes, hypertension, migraine, and previous thrombotic disease. Br. J. Obstet. Gynaecol. 102, 153-159 (1995).
34. Carolei A, Marini C, De Matteis G. History of migraine and the risk of cerebral ischaemia in young adults. The Italian National Research Council Study Group on Stroke in the Young. Lancet 347, 1503-1506 (1996).
35. Chang CL, Donaghy M, Poulter N. Migraine and stroke in young women: case-control study. The World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. BMJ 318, 13-18 (1999).
36. Donaghy M, Chang CL, Poulter N; European Collaborators of The World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Duration, frequency, recency, and type of migraine and the risk of ischaemic stroke in women of childbearing age. J. Neurol. Neurosurg. Psychiatry 73(6), 747-750 (2002).
37. Schwaag S, Nabavi DG, Frese A, Husstedt IW, Evers S. The association between migraine and juvenile stroke: a case-control study. Headache 43(2), 90-95 (2003).
38. Kruit MC, van Buchem MA, Hofman PA et al. Migraine as a risk factor for subclinical brain lesions. JAMA 291(4), 427-434 (2004).
39. Nightingale AL, Farmer RD. Ischemic stroke in young women: a nested case-control study using the UK General Practice Research Database. Stroke 35(7), 1574-1578 (2004).
40. Hall GC, Brown MM, Mo J. MacRae KD. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology 62(4), 563-568 (2004).
41. Velentgas P, Cole JA, Mo J, Sikes CR, Walker AM. Severe vascular events in migraine patients. Headache 44(7), 642-651 (2004).
42. Stang PE, Carson AP, Rose KM et al. Headache, cerebrovascular symptoms, and stroke: the Atherosclerosis Risk in Communities Study. Neurology 64(9), 1573-1577 (2005).
43. Kurth T, Slomke MA, Kase CS et al. Migraine, headache, and the risk of stroke in women: a prospective study. Neurology 64(6), 1020-1026 (2005).
44. Becker C, Brobert GP, Almqvist PM, Johansson S, Jick SS, Meier CR. Migraine and the risk of stroke, TIA, or death in the UK. Headache 47, 1374-1384 (2007).
45. Etminan M, Takkouche B, Isorna F, Samii A. Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. BMJ 330 (7482), 63 (2005).
46. Miller VM, Duckies SP. Vascular action of estrogens: functional implications. Pharmacol. Rev. 60, 210-241 (2008).
47. Schwartz SM, Petitti DB, Siscovick DS et al. Stroke and use of low-dose oral contraceptives in young women: a pooled analysis of two US studies. Stroke 29(11), 2277-2284 (1998).
48. Lidegaard Ø, Kreiner S. Contraceptives and cerebral thrombosis: a five-year national case-control study. Contraception 65(3), 197-205 (2002).
49. Macgregor EA. Migraine and use of combined hormonal contraceptives: a clinical review. J. Fam. Plann. Reprod. Health Care 33(3), 159-169 (2007).
50. Intiso D, Crociani P, Fogli D et al. Occurrence of factor V Leiden mutation (Arg506Gln) and anticardiolipin antibodies in migraine patients. Neurol. Sci. 22(6), 455-458 (2002).
51. D'Amico D, Moschiano F, Leone M et al. Genetic abnormalities of the protein C system: shared risk factors in young adults with migraine with aura and with ischemic stroke? Cephalalgia 18(9), 618-621 (1998).
52. Corral J, Iniesta JA, González-Conejero R, Lozano ML, Rivera J, Vicente V. Migraine and prothrombotic genetic risk factors. Cephalalgia 18(5), 257-260 (1998).
53. Kara I, Sazci A, Ergul E, Kaya G, Kilic G. Association of the C677T and A1298C polymorphisms in the 5,10 methylenetetrahydrofolate reductase gene in patients with migraine risk. Brain. Res. Mol. Brain Res. 111(1-2), 84-90 (2003).
54. Oterino A, Valle N, Bravo Y et al. MTHFR T677 homozygosis influences the presence of aura in migraineurs. Cephalalgia 24(6), 491-494 (2004).
55. Lea RA, Ovcaric M, Sundholm J, MacMillan J, Griffiths LR. The methylenetetrahydrofolate reductase gene variant C677T influences susceptibility to migraine with aura. BMC Med. 2, 3 (2004).
56. Boushey CJ, Beresfors SAA, Omenn GS, Motulky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folk acid intakes. JAMA 274, 1049-1057 (1995).
57. Martinelli I, Battaglioli T, Burgo I, Di Domenico S, Mannucci PM. Oral contraceptive use, thrombophilia and their interaction in young women with ischemic stroke. Haematologica 91, 844-847 (2006).
58. Moschiano F, D'Amico D, Usai S et al. Homocysteine plasma levels in patients with migraine with aura. Neurol. Sci. 29(Suppl. 1), S173-S175 (2008).
59. Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology 55(8), 1172-1179 (2000).
60. Anzola GP, Meneghetti G, Zanferrari C et al; SAM Study Group. Is migraine associated with right-to-left shunt a separate disease? Results of the SAM study. Cephalalgia 28(4), 360-366 (2008).
61. Botto N, Spadoni I, Giusti S, Ait-Ali L, Sicari R, Andreassi MG. Prothrombotic mutations as risk factors for cryptogenic ischemic cerebrovascular events in young subjects with patent foramen ovale. Stroke 38(7), 2070-2073 (2007).
62. Petitti DB, Sidney S, Quesenberry CP, Berstein A. Incidence of stroke and myocardial infarction in women of reproductive age. Stroke 28, 280-283 (1997).
63. Becker W Use of oral contraceptives in patients with migraine. Neurology 53(Suppl. 1), S19-S25 (1999).
64. Evans W, Becker MD. Migraine and oral contraceptives. Headache 46, 328-331 (2006).
65. Allais G, Castagnoli Gabellari I, De Lorenzo C, Mana O, Benedetto C. Menstrual migraine: clinical and therapeutical aspects. Expert. Rev. Neurother. 7(9), 1105-1120 (2007).
66. Sulak PJ, Kuehl TJ, Ortiz M, Shull BL. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am. J. Obstet. Gynecol. 186, 1142-1149 (2002).
67. Tietjen GE, Bushnell CD, Herial NA, Utley C, White L, Hafeez F. Endometriosis is associated with prevalence of comorbid conditions in migraine. Headache 47(7), 1069-1078 (2007).